Severe Ileocolonic Crohnʼs Disease Flare Associated with Fecal Microbiota Transplantation Requiring Diverting Ileostomy

Tran, Vivy; Phan, Jennifer; Nulsen, Benjamin; Huang, Lisa; Kaneshiro, Marc; Weiss, Guy A.; Ho, Wendy; Sack, Jonathan; Ha, Christina; Uslan, Daniel Z.; Sauk, Jenny

doi:10.14309/02075970-201805120-00013

Cited by 3 publications

(15 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rarely, unfavorable immunologic events in the gut after FMT may predispose to conditions such as Guillain-Barre syndrome [123]. Of concern with FMT is causation or worsening of a chronic disease such as inflammatory bowel disease [124][125][126].…”

Section: Potential Adverse Experiences From Fmtmentioning

confidence: 99%

Abnormal Intestinal Microbiome in Medical Disorders and Potential Reversibility by Fecal Microbiota Transplantation

et al. 2020

View full text Add to dashboard Cite

Reduction in diversity of the intestinal microbiome (dysbiosis) is being identified in many disease states, and studies are showing important biologic contributions of microbiome to health and disease. Fecal microbiota transplantation (FMT) is being evaluated as a way to reverse dysbiosis in diseases and disorders in an attempt to improve health. The published literature was reviewed to determine the value of FMT in the treatment of medical disorders for which clinical trials have recently been conducted. FMT is effective in treating recurrent C. difficile infection in one or two doses, with many healthy donors providing efficacious fecal-derived products. In inflammatory bowel disease (IBD), FMT may lead to remission in approximately one-third of moderate-to-severe illnesses with one study suggesting that more durable FMT responses may be seen when used once medical remissions have been achieved. Donor products differ in their efficacy in treatment of IBD. Combining donor products has been one way to increase the potential value of FMT in treating chronic disorders. FMT is being explored in a variety of clinical settings affecting different organ systems outside CDI, with positive preliminary signals, in treatment of functional constipation, immunotherapy-induced colitis, neurodegenerative disease, as well as prevention of cancer-related disorders like graft versus host disease and decolonization of patients with recurrent urinary tract infection due to antibiotic-resistant bacteria. Currently, intense research is underway to see how the microbiome products like FMT can be harnessed for health benefits.

show abstract

Section: Potential Adverse Experiences From Fmtmentioning

confidence: 99%

Abnormal Intestinal Microbiome in Medical Disorders and Potential Reversibility by Fecal Microbiota Transplantation

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Two cases of norovirus transmission have been reported in patients after receiving FMT from asymptomatic donors who did not have any sick contacts [48]. There have also been reports of inflammatory bowel disease flare-ups [49,50] following FMT, with the most serious adverse effect being the necessity of a colectomy. In a retrospective analysis by Cheng et al [49] a patient who needed a colectomy had cytomegalovirus colitis following FMT, which points to the importance of donor screening prior to FMT.…”

Section: Fecal Microbiota Transplantation (Fmt)mentioning

confidence: 99%

Treatment of Recurrent Clostridium difficile Infection

Johnson

Gerding

2019

JAMA

View full text Add to dashboard Cite

Recurrent Clostridium difficile infection (CDI) is a perpetual problem that leads to increased economic burden, higher healthcare cost, and significant morbidity and mortality. Its treatment remains a challenge. While various treatment approaches have been attempted with different levels of success, robust data establishing the superiority of one approach over the others is lacking. In this article, we review the current evidence pertaining to conventional pharmacological treatment as well as fecal microbiota transplantation (FMT) as a novel, rapidly emerging treatment modality for recurrent CDI.

show abstract

“…Studies indicate that the etiology of IBD is multifactorial, involving various influences, from environmental risk factors to microbial, genetic, and immune factors [ 6 , 7 , 8 ]. Current treatment guidelines for IBD focus on different strategies aimed at reducing inflammation and preventing additional extra digestive complications, such as arthritis and uveitis.…”

Section: Introductionmentioning

confidence: 99%

“…However, practitioners often face treatment limitations, including significant relapse rates, drug resistance, and immune tolerance to biological therapy. Despite the use and study of new molecules, there is no perfect treatment to cure CD or UC [ 6 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

“…As a result, researchers are actively exploring more effective treatment measures for IBD, and their recent studies have shown promising results in using FMT as a personalized therapy for recurrent or refractory IBD [ 6 ]. FMT represents the transfer of healthy fecal microbiota from a donor to a recipient, with the goal of improving microbial balance and modulating the immune response in the gut.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Exploring the Potential of Fecal Microbiota Transplantation as a Therapy in Tuberculosis and Inflammatory Bowel Disease

Boicean,

Bratu,

Fleaca

et al. 2023

Pathogens

View full text Add to dashboard Cite

This review explores the potential benefits of fecal microbiota transplantation (FMT) as an adjunct treatment in tuberculosis (TB), drawing parallels from its efficacy in inflammatory bowel disease (IBD). FMT has shown promise in restoring the gut microbial balance and modulating immune responses in IBD patients. Considering the similarities in immunomodulation and dysbiosis between IBD and TB, this review hypothesizes that FMT may offer therapeutic benefits as an adjunct therapy in TB. Methods: We conducted a systematic review of the existing literature on FMT in IBD and TB, highlighting the mechanisms and potential implications of FMT in the therapeutic management of both conditions. The findings contribute to understanding FMT’s potential role in TB treatment and underscore the necessity for future research in this direction to fully leverage its clinical applications. Conclusion: The integration of FMT into the comprehensive management of TB could potentially enhance treatment outcomes, reduce drug resistance, and mitigate the side effects of conventional therapies. Future research endeavors should focus on well-designed clinical trials to develop guidelines concerning the safety and short- and long-term benefits of FMT in TB patients, as well as to assess potential risks.

show abstract

Severe Ileocolonic Crohnʼs Disease Flare Associated with Fecal Microbiota Transplantation Requiring Diverting Ileostomy

Cited by 3 publications

References 11 publications

Abnormal Intestinal Microbiome in Medical Disorders and Potential Reversibility by Fecal Microbiota Transplantation

Abnormal Intestinal Microbiome in Medical Disorders and Potential Reversibility by Fecal Microbiota Transplantation

Treatment of Recurrent Clostridium difficile Infection

Exploring the Potential of Fecal Microbiota Transplantation as a Therapy in Tuberculosis and Inflammatory Bowel Disease

Contact Info

Product

Resources

About